Lumos Pharma Reports Positive Interim Results from Two Phase 2 Trials for Oral Lum-201 in Treating Moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency Introduction Lumos Pharma recently reported positive interim results from two Phase 2 trials evaluating LUM-201, a potential breakthrough in the treatment of Pediatric Growth Hormone Deficiency (PGHD). The trials have shown promising growth in pediatric…